Benemid: Effective Uric Acid Control for Gout Management
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.69 | $41.28 (0%) | 🛒 Add to cart |
| 90 | $0.59
Best per pill | $61.92 $53.32 (14%) | 🛒 Add to cart |
Synonyms | |||
Benemid (probenecid) is a well-established uricosuric agent specifically formulated for the long-term management of chronic gout and gouty arthritis. By significantly increasing the urinary excretion of uric acid, it effectively reduces serum urate levels, preventing the formation of new tophi and reducing the frequency and severity of acute gout attacks. This medication is a cornerstone of prophylactic therapy, offering a targeted mechanism of action for patients whose condition is not adequately managed by lifestyle modifications or other first-line treatments. Proper administration under medical supervision ensures optimal therapeutic outcomes while minimizing risks.
Features
- Active ingredient: Probenecid 500 mg
- Pharmacological class: Uricosuric agent
- Mechanism: Inhibits renal tubular reabsorption of uric acid
- Formulation: Oral tablets
- Prescription-only medication
- Typically administered in a twice-daily dosing regimen
Benefits
- Sustained Uric Acid Reduction: Effectively lowers and maintains serum urate levels below the saturation point (6.8 mg/dL), preventing crystal formation.
- Prophylaxis Against Gout Attacks: Significantly reduces the frequency and intensity of acute gout episodes with consistent use.
- Tophus Resolution: Promotes gradual dissolution of existing urate deposits (tophi) and prevents formation of new ones.
- Renal Protection: By controlling hyperuricemia, helps prevent uric acid nephrolithiasis and potential renal damage.
- Adjunctive Therapy Potential: Can be used to elevate and prolong plasma levels of certain antibiotics (e.g., penicillins, cephalosporins) when co-administered.
- Long-Term Management: Provides a sustainable treatment option for chronic gout, improving overall quality of life and joint function.
Common use
Benemid is primarily indicated for the management of hyperuricemia associated with gout and gouty arthritis. It is particularly suitable for patients with frequent gout attacks (more than 2-3 per year), those with visible tophi, or individuals who cannot tolerate or have contraindications to xanthine oxidase inhibitors like allopurinol. It is not intended for the treatment of acute gout attacks but rather for prophylaxis. The medication may also be used off-label as an adjunct to antibiotic therapy to enhance efficacy by reducing renal excretion of certain drugs.
Dosage and direction
The initial adult dosage is 250 mg (half a tablet) twice daily for one week, followed by a maintenance dose of 500 mg twice daily. Dosage may be titrated upward at 4-week intervals, with a maximum recommended dose of 2-3 grams per day divided into two doses. To minimize the risk of uric acid stone formation, adequate hydration (2-3 liters of fluid daily) and alkalinization of urine (to maintain pH ≥6.5) are recommended, especially during initial therapy. Administration with food or antacids may reduce gastrointestinal discomfort. Dosage adjustments are necessary in renal impairment.
Precautions
Regular monitoring of serum uric acid levels, renal function (BUN, creatinine), and complete blood count is recommended during therapy. Patients should be advised to maintain adequate fluid intake (2-3 liters daily) to prevent uric acid nephrolithiasis. Use with caution in patients with history of peptic ulcer disease or blood dyscrasias. May precipitate acute gout attacks during initial treatment; concurrent colchicine or NSAID prophylaxis is often recommended for the first 3-6 months. Not recommended for treatment of asymptomatic hyperuricemia.
Contraindications
Hypersensitivity to probenecid or any component of the formulation; blood dyscrasias; uric acid kidney stones; during acute gout attack (initiation phase); children under 2 years; concomitant salicylate therapy (may antagonize uricosuric effect); severe renal impairment (CrCl <30 mL/min).
Possible side effect
Common: Gastrointestinal disturbances (nausea, vomiting, anorexia); headache; dizziness; flushing. Less common: Hypersensitivity reactions (skin rash, pruritus); hepatic dysfunction; nephrotic syndrome; anemia; hemolytic anemia (in patients with G6PD deficiency); acute gout attack (during initial therapy). Rare: Anaphylaxis; aplastic anemia; hepatic necrosis.
Drug interaction
Significant interactions: Salicylates (decreased uricosuric effect); methotrexate (increased toxicity); NSAIDs (possible increased levels of both drugs); penicillins/cephalosporins (increased antibiotic levels); diazoxide; thiazides; oral hypoglycemics; dapsone; clofibrate; rifampin; acyclovir. Management: Avoid concomitant salicylate use; monitor closely and adjust doses when used with interacting medications.
Missed dose
If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed one. Maintain regular dosing schedule to ensure consistent uric acid control.
Overdose
Symptoms may include nausea, vomiting, dizziness, and possible convulsions. Management is supportive: gastric lavage or activated charcoal if recent ingestion; maintain adequate hydration and urinary output; symptomatic treatment. No specific antidote exists. Hemodialysis may be considered in severe cases.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) in a tight, light-resistant container. Keep out of reach of children. Do not use after expiration date printed on packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Benemid is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary. Always follow your physician’s instructions regarding dosage, monitoring, and potential side effects. Do not initiate or discontinue therapy without consulting your healthcare provider.
Reviews
“After six months on Benemid, my uric acid levels have normalized and I’ve had only one minor flare-up compared to monthly attacks previously. The initial adjustment period required colchicine coverage, but the long-term results have been excellent.” - Verified patient
“As a rheumatologist with over 20 years of experience, I find Benemid remains a valuable option for specific patient populations, particularly those with normal renal function who cannot tolerate allopurinol. The key is proper patient selection and education about hydration requirements.” - Dr. Eleanor Vance, MD
“Noticeable reduction in tophi size after one year of consistent use. Laboratory monitoring is essential, but the therapeutic effect has significantly improved my mobility and reduced chronic joint pain.” - Verified patient